Diabetes Therapy to Improve BMI and Lung Function in CF
Diabetes Therapy to Improve BMI and Lung Function in CF
To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting
 hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing
 the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize
 pulmonary function in cystic fibrosis (CF).
The primary objective of this research is to determine whether treatment with either insulin
 or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and
 pulmonary function in cystic fibrosis patients who have diabetes without fasting
 hyperglycemia.
-  Diabetic glucose pattern by oral glucose tolerance test (OGTT) of >200 at 120 min.
 (stable and healthy at time of OGTT)

 -  Fasting glucose levels <126.

 -  Weight stable within 5% in previous 3 months.

 -  Free from illness for two months.

 -  Male and female 16 and older, who are done growing

 -  Willing to come in for visits every 3 months.

 -  Patients receiving infrequent short bursts of systemic glucocorticoids may be
 considered for the study inclusion if: a. they have not received systemic
 glucocorticoids steroids for at least one month, b. they did not receive the steroids
 for more than 14 consecutive days or 28 days total in six months